# A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma

> **NCT03244306** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Seattle Children's Hospital** · enrollment: 4 (actual)

## Conditions studied

- Leukemia

## Interventions

- **BIOLOGICAL:** Patient-derived CD22-specific CAR T-cells also expressing an EGFRt

## Key facts

- **NCT ID:** NCT03244306
- **Lead sponsor:** Seattle Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-07-27
- **Primary completion:** 2018-11-14
- **Final completion:** 2035-07
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2025-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03244306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03244306, "A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03244306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*